ClinicalTrials.gg
Not yet recruitingNCT06097780STARUpdated Oct 24, 2023

Efficacy and Safety of NestaCell® in Huntington's Disease

A Phase 3 interventional study of NestaCell® in Huntington Disease, sponsored by Azidus Brasil. Not yet recruiting. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-10-24.

Sponsored by Azidus Brasil · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Huntington's disease (HD) is a rare neurodegenerative condition caused by increased CAG trinucleotide repeats in the HTT gene, on chromosome 4. The estimated global prevalence is 2.71 cases per 100,000 inhabitants. In Brazil, it is estimated that 13,000 to 19,000 people carry the gene and 65,000 to 95,000 are descendants at risk.

HD usually manifests itself in the fourth decade of life with motor, cognitive and behavioral symptoms, such as chorea. This condition profoundly affects quality of life and there is no treatment that can modify its course. Tetrabenazine is the only medication approved to control chorea.

A partnership between the Butantan Institute and Cellavita investigates the use of Human Dental Pulp Stem Cells (hDPSCs) to treat HD. NestaCell® was developed, a product based on these cells, which express high levels of BDNF, an important neurotrophic factor for neuronal survival.

Preclinical tests showed that NestaCell® is distributed to several organs, including the central nervous system, being well tolerated in toxicological tests in rats.

In phase I (SAVE) and phase II (ADORE) clinical trials, NestaCell® was administered to patients with HD. The results indicated a significant improvement in motor scores and functional capacity compared to placebo, demonstrating a clinically significant benefit.

NestaCell® also presented a good safety and tolerability profile, with few adverse events related to the product. The results support the conclusion that NestaCell® is safe and well tolerated in HD patients, within the doses tested.

Read the detailed description

This is a Phase III multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of Nestacell® in Huntington's Disease.

After signing the Informed Consent Form (ICF) the patients will perform the V-2 and V-1 screening procedures. In the V-2 the site collects personal data and a physician clinically confirms the HD diagnosis. The patient collects blood for CAG repeats and safety exams. Females with childbearing potential perform a urine pregnancy test. In the V-1 the investigator remotely reviews the results of the V-2 exams and authorizes the performance of the V-1 radiological exams (MRI and Total-Body PET Scan) in the radiology center.

In the V0, the PI and his team perform the baseline UHDRS and body weight assessments. The patient will be randomized to Nestacell® or placebo. Those weighing 50 to 67.9 kg will receive 100 million cells (or placebo) and those weighing ≥ 68 kg will receive 136 million cells(or placebo) per administration. The doses are based on the V0 weight assessment and will not change throughout the study unless the PI asks for safety reasons (for example, a relevant weight loss).

The V1 marks the first investigational product administration. It will happen in sites unrelated to those performing the outcomes evaluation by personnel specially trained to prepare and administer the investigational product. After the females with childbearing potential performe the urine pregnancy test, NestaCell® or placebo will be administered intravenously in three cycles of three-monthly administrations with a monthly interval between cycles (total of 9 administrations). The other administrations happen at visits V2, V3, V5, V6, V7, V9, V10, and V11. To assure blindness, UHDRS and other clinical evaluations will be carried out in the research center [by the principal investigator (PI)] while the administrations will be made in the Center for the Investigational Product Administration (CIPA). The outcome evaluations by the PI and his/her team happen at V4, V8, and V12, one month after the end of each cycle. In the V13, the patients will also be directed to the radiology center to repeat the MRI exam.

Each patient participates in the trial for approximately 14 months, two months for screening, and twelve months for investigational product administration and follow-up.

02

Conditions studied

  • Huntington Disease

Browse trials for

Keywords

  • STAR
  • NestaCell ®
03

In context

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

This study's planned enrollment of 120 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.

Browse Huntington Disease studies →

Lead sponsor

Azidus Brasil is the lead sponsor of 80 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female;
  2. Age from 18 to 55 years;
  3. HD diagnostic confidence level (DCL) score of 3 or 4 at enrolment;
  4. HD manifestations begin from 4 to 8 years before enrolment;
  5. UHDRS Total Functional Capacity (TFC) from 7 to 12, suggesting mild-moderate functional impairment;
  6. Body weight at the V -1 from 50 to 90 Kg;
  7. CAG repeats from 40 to 50;
  8. ICF signature.

Exclusion criteria

Exclusion Criteria:

  1. Juvenile Huntington's disease,
  2. Concomitant epilepsy;
  3. Decompensated psychiatric disorders;
  4. History of a suicide attempt;
  5. Other neurological or musculoskeletal disorders that might interfere with the assessments;
  6. Prior use of gene or cell therapy.
  7. Confirmed or suspected cancer within the last 1 year (except operated basal cell carcinoma);
  8. History of allergy to imaging exams contrast, or bovine origin products;
  9. Current or planned use of ;
  10. changes in the safety exams, defined as;

    • Serum transaminases (, AST) increased > 2.5 × upper limit of normality ().
    • in peripheral blood \< 3,000 cells/1 mm3.
    • Serum creatinine > 2 × age- and sex-specific ULN.
    • Positive serology for 1 and 2 (Anti-HIV-1,2), HTLV I and II, (HBsAg, Anti-HBc), (anti-HCV-Ab), and FTA-ABS.
    • Amylase, Troponin I, CKmB increased > 2.0 × ULN.
    • shown by the Total-Body PET Scan.
    • > 6.5%.
    • , TT, > 2.5 x ULN.
  11. Pregnancy, lactation, or pregnancy plan;
  12. less than 18.5 at enrolment;
  13. Participation in a clinical trial within twelve months before inclusion;
  14. History of surgical procedures aiming at improving symptoms of Huntington's disease, such as neural transplantations, lesions of the central nervous system, infusions of neurotrophic agents, or deep brain stimulation.
  15. Any medical condition that makes the patient unsuitable for the study or increases the risk of participation at the investigator's discretion.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Arm 1: Nine intravenous placebo administrations in twelve months.

    Genetic: NestaCell®

  • Experimental
    Intravenous NestaCell® administrations

    Arm 2: Nine intravenous NestaCell® administrations in twelve months.

    Genetic: NestaCell®

Interventions

  • GeneticNestaCell®

    Human Dental Pulp Stem Cells (hDPSCs).

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Objective

    Proportion of patients who stabilized or decreased the UHDRS-TMS from Visit 0 to Visit 12 in the Nestacell® vs. Placebo groups.

    Time frame: 1 year

Secondary outcomes

  1. Secondary Efficacy Objectives

    Mean variation of the UHDRS-TMS mean variation from Visit 0 to Visit 12 in the groups Nestacell® and Placebo.

    Time frame: 1 year

  2. Secondary Efficacy Objectives

    Proportion of patients who stabilized or increased the UHDRS-TFC from Visit 0 to Visit 12 in the groups Nestacell® and Placebo.

    Time frame: 1 year

  3. Secondary Efficacy Objectives

    Mean variation of the UHDRS-TFC from Visit 0 to Visit 12 of the groups Nestacell® and Placebo.

    Time frame: 1 year

  4. Secondary Efficacy Objectives

    Proportion of patients who stabilized or increased the cUHDRS from Visit 0 to Visit 12 in the groups Nestacell® and Placebo.

    Time frame: 1 year

  5. Secondary Efficacy Objectives

    Mean variation of the cUHDRS from Visit 0 to Visit 12 of the groups Nestacell® and Placebo.

    Time frame: 1 year

  6. Secondary Efficacy Objectives

    Proportion of patients who stabilized the MRI outcomes: 7.1 white substance, 7.2 gray substance, from Visit 0 to Visit 12 in the groups Nestacell® and Placebo.

    Time frame: 1 year

  7. Secondary Efficacy Objectives

    Mean variation of the MRI outcomes: 8.1 white substance, 8.2 gray substance, from Visit 0 to Visit 12 in the groups Nestacell® and Placebo.

    Time frame: 1 year

  8. Secondary Efficacy Objectives

    Proportion of patients who stabilized or decreased the NfL blood levels from Visit 0 to Visit 12 in the groups Nestacell® and Placebo.

    Time frame: 1 year

  9. Secondary Efficacy Objectives

    Mean variation of the NfL blood levels from Visit 0 to Visit 12 of the groups Nestacell® and Placebo.

    Time frame: 1 year

Other outcomes

  1. Secondary Safety Objective

    Occurrence, severity and cause of adverse events related to the study drug

    Time frame: 1 year

  2. Exploratory objectives

    Blood concentration of nestin, IL-6, IL-17, TNFα, IFN-γ, C-reactive protein, BDNF, PT, aPTT, and D-dimer and the saliva concentration of BDNF and huntingtin before and 24 h after the NestaCell® administration at V1 and in a subset of 20-30 HD patients.

    Time frame: 1 year

  3. Exploratory objectives

    Blood concentration of nestin, IL-6, IL-17, TNFα, IFN-γ, C-reactive protein, BDNF, PT, aPTT, and D-dimer and the saliva concentration of BDNF and huntingtin before and 24 h after the NestaCell® administration at V9 in a subset of 20-30 HD patients.

    Time frame: Up to 9 months

  4. Exploratory objectives

    Evolution between V1 and V9 of the blood concentration of nestin, IL-6, IL-17, TNFα, IFN-γ, C-reactive protein, BDNF, PT, aPTT, and D-dimer and the saliva concentration of BDNF and huntingtin before the NestaCell® administration in a subset of 20-30 HD patients

    Time frame: Up to 9 months

  5. Exploratory objectives

    Evolution between V1 and V9 of the blood concentration of nestin, IL-6, IL-17, TNFα, IFN-γ, C-reactive protein, BDNF, PT, aPTT, and D-dimer and the saliva concentration of BDNF and huntingtin 24 hours after the NestaCell® administration in a subset of 20-30 HD patients.

    Time frame: Up to 9 months

  6. Exploratory objectives

    Measure of the relative amount of study participants who experienced changes in hair color during the course of the study.Nestacell® and placebo groups.

    Time frame: 1 year

  7. Exploratory objectives

    Measure of the relative number of study participants who experienced hair growth.

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • ABH - Associação Brasil Huntington. p. Perguntas Frequentes. Disponível em: https://abh.org.br/perguntas-frequentes/. Acesso em: 19/12/2022.
  • BARRETO, R. D. R. Características da Disfunção Congnitiva na Doença de Huntington. Orientador: JANUÁRIO, D. C. 2009. 87 f. (Mestre) - Faculdade de Medicina, Universidade de Coimbra.
  • Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015 Dec 10;11(6):1164-78. doi: 10.5114/aoms.2015.56342. Epub 2015 Dec 11. PubMed 26788077 ↗
  • Baydyuk M, Xu B. BDNF signaling and survival of striatal neurons. Front Cell Neurosci. 2014 Aug 28;8:254. doi: 10.3389/fncel.2014.00254. eCollection 2014. PubMed 25221473 ↗
  • Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R; Multiple Sclerosis Outcome Assessments Consortium. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017 Apr;23(5):721-733. doi: 10.1177/1352458517690821. Epub 2017 Feb 16. PubMed 28206827 ↗
  • BENTON, A. L.; HAMSHER, K. S.; SIVAN, A. B.; PSYCHOLOGICAL ASSESSMENT RESOURCES, I. Multilingual Aphasia Examination, Third Edition: Manual of instructions. PAR, 1978.
  • Biglan KM, Zhang Y, Long JD, Geschwind M, Kang GA, Killoran A, Lu W, McCusker E, Mills JA, Raymond LA, Testa C, Wojcieszek J, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci. 2013 Apr 2;5:12. doi: 10.3389/fnagi.2013.00012. eCollection 2013. PubMed 23565093 ↗
  • Chen J, Marks E, Lai B, Zhang Z, Duce JA, Lam LQ, Volitakis I, Bush AI, Hersch S, Fox JH. Iron accumulates in Huntington's disease neurons: protection by deferoxamine. PLoS One. 2013 Oct 11;8(10):e77023. doi: 10.1371/journal.pone.0077023. eCollection 2013. Erratum In: PLoS One. 2013;8(11). doi:10.1371/annotation/67f555f5-35b7-4468-8bab-26d518942803. PubMed 24146952 ↗
  • Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AF, Biglan KM, Shoulson I; Huntington Study Group COHORT Investigators. Natural history of Huntington disease. JAMA Neurol. 2013 Dec;70(12):1520-30. doi: 10.1001/jamaneurol.2013.4408. PubMed 24126537 ↗
  • FDA. Guidance for Industry: Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products. pp. 27.
  • Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM; Huntington Study Group/ARC-HD Investigators and Coordinators. The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study. CNS Drugs. 2022 Nov;36(11):1207-1216. doi: 10.1007/s40263-022-00956-8. Epub 2022 Oct 15. PubMed 36242718 ↗
  • GAMARRA, L.; CINTRA, L.; GÁRATE, A. P. Relatório Final do Estudo de Biodistribuição do Produto NestaCell®. Centro de Experimentação e Treinamento em Cirurgia (CETEC) do Instituto Israelita de Ensino e Pesquisa Hospital Albert Einstein, p. 72. 2022.
  • Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord. 1996 Mar;11(2):136-42. doi: 10.1002/mds.870110204. PubMed 8684382 ↗
  • JANUÁRIO, C. Doença de Huntington. Onde estamos agora? 2011. 148 f. (Doutor) -, Universidade de Coimbra.
  • Muller M, Leavitt BR. Iron dysregulation in Huntington's disease. J Neurochem. 2014 Aug;130(3):328-50. doi: 10.1111/jnc.12739. Epub 2014 May 28. PubMed 24717009 ↗
  • Niu L, Ye C, Sun Y, Peng T, Yang S, Wang W, Li H. Mutant huntingtin induces iron overload via up-regulating IRP1 in Huntington's disease. Cell Biosci. 2018 Jul 4;8:41. doi: 10.1186/s13578-018-0239-x. eCollection 2018. PubMed 30002810 ↗
  • PATTERSON, J. Verbal Fluency. In: KREUTZER, J. S.;DELUCA, J., et al (Ed.). Encyclopedia of Clinical Neuropsychology. New York, NY: Springer New York, 2011. p. 2603-2606.
  • Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012 Aug;27(9):1083-91. doi: 10.1002/mds.25075. Epub 2012 Jun 12. PubMed 22692795 ↗
  • Resolução CNS nº 466. Brasília: Conselho Nacional de Saúde 2012.
  • Resolução RDC n°508. Brasilia: Conselho Nacional de Saúde 2021.
  • SPREEN, O.; SPREEN, B. P. P. O.; STRAUSS, E.; STRAUSS, P. P. E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Oxford University Press, USA, 1998. 9780195100198.
  • Tumas V, Camargos ST, Jalali PS, Galesso Ade P, Marques W Jr. Internal consistency of a Brazilian version of the unified Huntington's disease rating scale. Arq Neuropsiquiatr. 2004 Dec;62(4):977-82. doi: 10.1590/S0004-282X2004000600009. Epub 2004 Dec 15. PubMed 15608955 ↗
  • Walker FO. Huntington's disease. Lancet. 2007 Jan 20;369(9557):218-28. doi: 10.1016/S0140-6736(07)60111-1. PubMed 17240289 ↗
  • Wenceslau CV, de Souza DM, Mambelli-Lisboa NC, Ynoue LH, Araldi RP, da Silva JM, Pagani E, Haddad MS, Kerkis I. Restoration of BDNF, DARPP32, and D2R Expression Following Intravenous Infusion of Human Immature Dental Pulp Stem Cells in Huntington's Disease 3-NP Rat Model. Cells. 2022 May 17;11(10):1664. doi: 10.3390/cells11101664. PubMed 35626701 ↗

Individual participant data

Plan to share: No — After the data analysis and presentation to the National Commission on Research Ethics, all data of the study will become public.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2024; primary completion for Sep 2025, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Oct 24, 2023
StartEst.
Jun 8, 2024
Primary completionEst.
Sep 8, 2025
CompletionEst.
Feb 9, 2026
Last update
Oct 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06097780
Lead sponsor
Azidus Brasil
Collaborators
Cellavita Pesquisa Científica Ltda
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Jun 8, 2024 (estimated)
Primary completion
Sep 8, 2025 (estimated)
Completion
Feb 9, 2026 (estimated)
Last update
Oct 24, 2023

Study contacts

Luciana Ferrara, Doctor
Contact
luciana.ferrara@azidusbrasil.com.br
+ 55 19 981428814
Luciana Ferrara, Doctor
study director · Azidus Brasil

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion